{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:18:34Z","timestamp":1790965114177,"version":"4.1.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2013,5,16]],"date-time":"2013-05-16T00:00:00Z","timestamp":1368662400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Neuropathol"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s00401-013-1128-3","type":"journal-article","created":{"date-parts":[[2013,5,15]],"date-time":"2013-05-15T09:15:17Z","timestamp":1368609317000},"page":"829-840","source":"Crossref","is-referenced-by-count":65,"title":["C1q-targeted monoclonal antibody prevents complement-dependent cytotoxicity and neuropathology in in vitro and mouse models of neuromyelitis optica"],"prefix":"10.1007","volume":"125","author":[{"given":"Puay-Wah","family":"Phuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nithi","family":"Asavapanumas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Leviten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukmanee","family":"Tradtrantip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. S.","family":"Verkman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,5,16]]},"reference":[{"issue":"6","key":"1128_CR1","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3109\/07853890.2012.687833","volume":"44","author":"W Aberer","year":"2012","unstructured":"Aberer W (2012) Hereditary angioedema treatment options: the availability of new therapies. Ann Med 44(6):523\u2013529","journal-title":"Ann Med"},{"issue":"1\u20132","key":"1128_CR2","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jneuroim.2012.09.010","volume":"254","author":"N Asgari","year":"2013","unstructured":"Asgari N, Khorooshi R, Lillevang ST, Owens T (2013) Complement-dependent pathogenicity of brain-specific antibodies in cerebrospinal fluid. J Neuroimmunol 254(1\u20132):76\u201382","journal-title":"J Neuroimmunol"},{"issue":"3","key":"1128_CR3","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1001\/jamaneurol.2013.1246","volume":"70","author":"I Ayzenberg","year":"2013","unstructured":"Ayzenberg I, Kleiter I, Schr\u00f6der A, Hellwig K, Chan A, Yamamura T, Gold R (2013) Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol 70(3):394\u2013397","journal-title":"JAMA Neurol"},{"issue":"5","key":"1128_CR4","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ana.21802","volume":"66","author":"JL Bennett","year":"2009","unstructured":"Bennett JL, Lam C, Kalluri SR, Saikali P, Bautista K, Dupree C, Glogowska M, Case D, Antel JP, Owens GP, Gilden D, Nessler S, Stadelmann C, Hemmer B (2009) Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 66(5):617\u2013629","journal-title":"Ann Neurol"},{"key":"1128_CR5","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/ng0598-56","volume":"19","author":"M Botto","year":"1998","unstructured":"Botto M, Agnola CD, Bygrave AE, Thompson EM, Cook HT, Petry F, Loos M, Pandolfi PP, Walport MJ (1998) Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 19:56\u201359","journal-title":"Nat Genet"},{"key":"1128_CR6","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1078\/0171-2985-00141","volume":"205","author":"M Botto","year":"2002","unstructured":"Botto M, Walport MJ (2002) C1q, autoimmunity and apoptosis. Immunobiol 205:395\u2013406","journal-title":"Immunobiol"},{"issue":"18","key":"1128_CR7","doi-asserted-by":"crossref","first-page":"16516","DOI":"10.1074\/jbc.M111.227298","volume":"286","author":"JM Crane","year":"2011","unstructured":"Crane JM, Lam C, Rossi A, Gupta T, Bennett JL, Verkman AS (2011) Binding affinity and specificity of neuromyelitis optica autoantibodies to aquaporin-4 M1\/M23 isoforms and orthogonal arrays. J Biol Chem 286(18):16516\u201316524","journal-title":"J Biol Chem"},{"issue":"49","key":"1128_CR8","doi-asserted-by":"crossref","first-page":"13093","DOI":"10.1021\/bi801131h","volume":"47","author":"MG Gadjeva","year":"2008","unstructured":"Gadjeva MG, Rouseva MM, Zlatarova AS, Reid KBM, Kishore U, Kojouharova MS (2008) Interaction of human C1q with IgG and IgM: revisited. Biochemistry 47(49):13093\u201313102","journal-title":"Biochemistry"},{"issue":"Suppl 1","key":"1128_CR9","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.2500\/aap.2012.33.3555","volume":"33","author":"MS Georgy","year":"2012","unstructured":"Georgy MS, Pongracic JA (2012) Chapter 22: hereditary and acquired angioedema. Allergy Asthma Proc 33(Suppl 1):S73\u2013S76","journal-title":"Allergy Asthma Proc"},{"issue":"4\u20135","key":"1128_CR10","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.imbio.2006.11.001","volume":"212","author":"R Ghai","year":"2007","unstructured":"Ghai R, Waters P, Roumenina LT, Gadjeva M, Kojouharova MS, Reid KB, Sim RB, Kishore U (2007) C1q and its growing family. Immunobiol 212(4\u20135):253\u2013266","journal-title":"Immunobiol"},{"issue":"Suppl 1","key":"1128_CR11","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1179\/102453312X13336169155213","volume":"17","author":"D G\u00f3mez-Almaguer","year":"2012","unstructured":"G\u00f3mez-Almaguer D (2012) Monoclonal antibodies in the treatment of immune thrombocytopenic purpura (ITP). Hematology 17(Suppl 1):S25\u2013S27","journal-title":"Hematology"},{"key":"1128_CR12","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3109\/08916930903555943","volume":"43","author":"AM Gomez","year":"2010","unstructured":"Gomez AM, Van Den Broeck J, Vrolix K, Janssen SP, Lemmens MA, Van Der Esch E, Duimel H, Frederik P, Molenaar PC, Mart\u00ednez-Mart\u00ednez P, De Baets MH, Losen M (2010) Antibody effector mechanisms in myasthenia gravis pathogenesis at the neuromuscular junction. Autoimmunity 43:353\u2013370","journal-title":"Autoimmunity"},{"issue":"7","key":"1128_CR13","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1177\/1352458511432896","volume":"18","author":"BM Greenberg","year":"2012","unstructured":"Greenberg BM, Graves D, Remington G, Hardeman P, Mann M, Karandikar N, Stuve O, Monson N, Frohman E (2012) Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success. Mult Scler 18(7):1022\u20131026","journal-title":"Mult Scler"},{"issue":"5","key":"1128_CR14","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1177\/1352458506070145","volume":"13","author":"GJ Hengstman","year":"2007","unstructured":"Hengstman GJ, Wesseling P, Frenken CW, Jongen PJ (2007) Neuromyelitis optica with clinical and histopathological involvement of the brain. Mult Scler 13(5):679\u2013682","journal-title":"Mult Scler"},{"key":"1128_CR15","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1001\/archneurol.2009.188","volume":"66","author":"SR Hinson","year":"2009","unstructured":"Hinson SR, McKeon A, Fryer JP, Apiwattanakul M, Lennon VA, Pittock SJ (2009) Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells. Arch Neurol 66:1164\u20131167","journal-title":"Arch Neurol"},{"issue":"24","key":"1128_CR16","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1212\/01.WNL.0000289761.64862.ce","volume":"69","author":"SR Hinson","year":"2007","unstructured":"Hinson SR, Pittock SJ, Lucchinetti CF, Roemer SF, Fryer JP, Kryzer TJ, Lennon VA (2007) Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 69(24):2221\u20132231","journal-title":"Neurology"},{"key":"1128_CR17","first-page":"475","volume":"19","author":"A Jacob","year":"2013","unstructured":"Jacob A, McKeon A, Nakashima I, Sato DK, Elsone L, Fujihara K, de Seze J (2013) Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. J Neurol Neurosurg Psych 19:475\u2013479","journal-title":"J Neurol Neurosurg Psych"},{"issue":"4","key":"1128_CR18","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/ncpneuro0764","volume":"4","author":"S Jarius","year":"2008","unstructured":"Jarius S, Paul F, Franciotta D, Waters P, Zipp F, Hohlfeld R, Vincent A, Wildemann B (2008) Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol 4(4):202\u2013214","journal-title":"Nat Clin Pract Neurol"},{"issue":"7","key":"1128_CR19","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrneurol.2010.72","volume":"6","author":"S Jarius","year":"2010","unstructured":"Jarius S, Wildemann B (2010) AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nature Rev Neurol 6(7):383\u2013392","journal-title":"Nature Rev Neurol"},{"key":"1128_CR20","first-page":"1","volume":"24","author":"BC Kieseier","year":"2012","unstructured":"Kieseier BC, St\u00fcve O, Dehmel T, Goebels N, Leussink VI, Mausberg AK, Ringelstein M, Turowski B, Aktas O, Antoch G, Hartung HP (2012) Disease amelioration with Tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. Arch Neurol 24:1\u20134","journal-title":"Arch Neurol"},{"issue":"1","key":"1128_CR21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3988\/jcn.2013.9.1.36","volume":"9","author":"SH Kim","year":"2013","unstructured":"Kim SH, Kim W, Huh SY, Lee KY, Jung IJ, Kim HJ (2013) Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti-aquaporin-4 antibody levels. J Clin Neurol 9(1):36\u201342","journal-title":"J Clin Neurol"},{"issue":"1\u20132","key":"1128_CR22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jns.2011.08.043","volume":"311","author":"J Kira","year":"2011","unstructured":"Kira J (2011) Autoimmunity in neuromyelitis optica and opticospinal multiple sclerosis: astrocytopathy as a common denominator in demyelinating disorders. J Neurol Sci 311(1\u20132):69\u201377","journal-title":"J Neurol Sci"},{"key":"1128_CR23","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0162-3109(00)80301-X","volume":"49","author":"U Kishore","year":"2000","unstructured":"Kishore U, Reid KBM (2000) C1q: structure, function, and receptors. Immunopharmacol 49:159\u2013170","journal-title":"Immunopharmacol"},{"issue":"14","key":"1128_CR24","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1016\/j.molimm.2009.04.027","volume":"46","author":"A Klos","year":"2009","unstructured":"Klos A, Tenner AJ, Johswich KO, Ager RR, Reis ES, K\u00f6hl J (2009) The role of the anaphylatoxins in health and disease. Mol Immunol 46(14):2753\u20132766","journal-title":"Mol Immunol"},{"issue":"1\u20132","key":"1128_CR25","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jneuroim.2012.09.002","volume":"254","author":"H Kuroda","year":"2013","unstructured":"Kuroda H, Fujihara K, Takano R, Takai Y, Takahashi T, Misu T, Nakashima I, Sato S, Itoyama Y, Aoki M (2013) Increase of complement fragment C5a in cerebrospinal fluid during exacerbation of neuromyelitis optica. J Neuroimmunol 254(1\u20132):178\u2013182","journal-title":"J Neuroimmunol"},{"issue":"4","key":"1128_CR26","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","volume":"202","author":"VA Lennon","year":"2005","unstructured":"Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202(4):473\u2013477","journal-title":"J Exp Med"},{"issue":"Pt 7","key":"1128_CR27","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/brain\/awf151","volume":"125","author":"CF Lucchinetti","year":"2002","unstructured":"Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, Trebst C, Weinshenker B, Wingerchuk D, Parisi JE, Lassmann H (2002) A role for humoral mechanisms in the pathogenesis of Devic\u2019s neuromyelitis optica. Brain 125(Pt 7):1450\u20131461","journal-title":"Brain"},{"key":"1128_CR28","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/1742-2094-8-184","volume":"8","author":"S Mader","year":"2011","unstructured":"Mader S, Gredler V, Schanda K, Rostasy K, Dujmovic I, Pfaller K, Lutterotti A, Jarius S, Di Pauli F, Kuenz B, Ehling R, Hegen H, Deisenhammer F, Aboul-Enein F, Storch MK, Koson P, Drulovic J, Kristoferitsch W, Berger T, Reindl M (2011) Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation 8:184","journal-title":"J Neuroinflammation"},{"key":"1128_CR29","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1146\/annurev.immunol.22.012703.104549","volume":"22","author":"AP Manderson","year":"2004","unstructured":"Manderson AP, Botto M, Walport MJ (2004) The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol 22:431\u2013456","journal-title":"Annu Rev Immunol"},{"issue":"Pt 5","key":"1128_CR30","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1093\/brain\/awm047","volume":"130","author":"T Misu","year":"2007","unstructured":"Misu T, Fujihara K, Kakita A, Konno H, Nakamura M, Watanabe S, Takahashi T, Nakashima I, Takahashi H, Itoyama Y (2007) Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 130(Pt 5):1224\u20131234","journal-title":"Brain"},{"issue":"2","key":"1128_CR31","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1177\/1753425910396252","volume":"18","author":"A Nayak","year":"2012","unstructured":"Nayak A, Pedneka L, Reid KB, Kishore U (2012) Complement and non-complement activating functions of C1q: a prototypical innate immune molecule. Innate Immun 18(2):350\u2013363","journal-title":"Innate Immun"},{"issue":"6","key":"1128_CR32","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1474-4422(12)70133-3","volume":"11","author":"MC Papadopoulos","year":"2012","unstructured":"Papadopoulos MC, Verkman AS (2012) Aquaporin 4 and neuromyelitis optica. Lancet Neurol 11(6):535\u2013544","journal-title":"Lancet Neurol"},{"issue":"9665","key":"1128_CR33","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(09)60001-5","volume":"373","author":"C Parker","year":"2009","unstructured":"Parker C (2009) Eculizumab for paroxysmal nocturnal haemoglobinuria. Lancet 373(9665):759\u2013767","journal-title":"Lancet"},{"issue":"17","key":"1128_CR34","doi-asserted-by":"crossref","first-page":"13829","DOI":"10.1074\/jbc.M112.344325","volume":"287","author":"PW Phuan","year":"2012","unstructured":"Phuan PW, Ratelade J, Rossi A, Tradtrantip L, Verkman AS (2012) Complement-dependent cytotoxicity in neuromyelitis optica requires aquaporin-4 protein assembly in orthogonal arrays. J Biol Chem 287(17):13829\u201313839","journal-title":"J Biol Chem"},{"key":"1128_CR35","doi-asserted-by":"crossref","unstructured":"Pittock SJ, Lennon VA, McKeon A, Mandrekar J, Weinshenker BG, Lucchinetti CF, O\u2019Toole O, Wingerchuk DM (2013) Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol (in press)","DOI":"10.1016\/S1474-4422(13)70076-0"},{"issue":"6","key":"1128_CR36","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00401-012-0986-4","volume":"123","author":"J Ratelade","year":"2012","unstructured":"Ratelade J, Zhang H, Saadoun S, Bennett JL, Papadopoulos MC, Verkman AS (2012) Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss. Acta Neuropathol 123(6):861\u2013872","journal-title":"Acta Neuropathol"},{"issue":"2","key":"1128_CR37","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","volume":"83","author":"ME Reff","year":"1994","unstructured":"Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83(2):435\u2013445","journal-title":"Blood"},{"issue":"9","key":"1128_CR38","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/ni.1923","volume":"11","author":"D Ricklin","year":"2010","unstructured":"Ricklin D, Hajishengallis G, Lambris JD (2010) Complement: a key system for immune surveillance and homeostatis. Nat Immunol 11(9):785\u2013797","journal-title":"Nat Immunol"},{"key":"1128_CR39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4614-4118-2_1","volume":"735","author":"D Ricklin","year":"2013","unstructured":"Ricklin D, Lambris JD (2013) Progress and trends in complement therapeutics. Adv Exp Med Biol 735:1\u201322","journal-title":"Adv Exp Med Biol"},{"key":"1128_CR40","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/978-1-4614-4118-2_10","volume":"735","author":"AM Risitano","year":"2013","unstructured":"Risitano AM (2013) Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies. Adv Exp Med Biol 735:155\u2013172","journal-title":"Adv Exp Med Biol"},{"issue":"Pt 5","key":"1128_CR41","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/brain\/awl371","volume":"130","author":"SF Roemer","year":"2007","unstructured":"Roemer SF, Parisi JE, Lennon VA, Benarroch EE, Lassmann H, Bruck W, Mandler R, Weinshenker BG, Pittsock SJ, Wingerchuk DM, Lucchinetti CF (2007) Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 130(Pt 5):1194\u20131205","journal-title":"Brain"},{"issue":"Pt 2","key":"1128_CR42","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/brain\/awp309","volume":"133","author":"S Saadoun","year":"2010","unstructured":"Saadoun S, Waters P, Bell BA, Vincent A, Verkman AS, Papadopoulos MC (2010) Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 133(Pt 2):349\u2013361","journal-title":"Brain"},{"issue":"3","key":"1128_CR43","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/ana.22686","volume":"71","author":"S Saadoun","year":"2012","unstructured":"Saadoun S, Waters P, MacDonald C, Bell BA, Vincent A, Verkman AS, Papadopoulos MC (2012) Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain. Ann Neurol 71(3):323\u2013333","journal-title":"Ann Neurol"},{"key":"1128_CR44","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jneuroim.2009.07.014","volume":"215","author":"L Sabater","year":"2009","unstructured":"Sabater L, Giralt A, Boronat A, Hankiewicz K, Blanco Y, Llufriu S, Alberch J, Graus F, Saiz A (2009) Cytotoxic effect of neuromyelitis optica antibody (NMO-IgG) to astrocytes: an in vitro study. J Neuroimmunol 215:31\u201335","journal-title":"J Neuroimmunol"},{"issue":"1","key":"1128_CR45","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1590\/S0004-282X2012000100012","volume":"70","author":"D Sato","year":"2012","unstructured":"Sato D, Callegaro D, Lana-Peixoto MA, Fujihara K (2012) Treatment of neuromyelitis optica: an evidence based review. Arq Neuropsiquiatr 70(1):59\u201366","journal-title":"Arq Neuropsiquiatr"},{"key":"1128_CR46","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.4049\/jimmunol.164.10.5446","volume":"164","author":"MK Sch\u00e4fer","year":"2000","unstructured":"Sch\u00e4fer MK, Schwaeble WJ, Post C, Salvati P, Calabresi M, Sim RB, Petry F, Loos M, Weihe E (2000) Complement C1q is dramatically up-regulated in brain microglia in response to transient global cerebral ischemia. J Immunol 164:5446\u20135452","journal-title":"J Immunol"},{"issue":"11","key":"1128_CR47","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1161\/01.CIR.98.11.1085","volume":"98","author":"SH Tam","year":"1998","unstructured":"Tam SH, Sassoli PM, Jordan RE, Nakada MT (1998) Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb\/IIIa and \u03b1\u03bd\u03b23 integrins. Circulation 98(11):1085\u20131091","journal-title":"Circulation"},{"key":"1128_CR48","doi-asserted-by":"crossref","unstructured":"Tradtrantip L, Asavapanumas N, Verkman AS (2013) Therapeutic cleavage of anti-aquaporin-4 autoantibody in neuromyelitis optica by an IgG-selective proteinase. Mol Pharmacol (in press)","DOI":"10.1124\/mol.113.086470"},{"issue":"1","key":"1128_CR49","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/ana.23741","volume":"73","author":"L Tradtrantip","year":"2013","unstructured":"Tradtrantip L, Ratelade J, Zhang H, Verkman AS (2013) Enzymatic deglycosylation converts pathogenic neuromyelitis optica anti-aquaporin-4 immunoglobulin G into therapeutic antibody. Ann Neurol 73(1):77\u201385","journal-title":"Ann Neurol"},{"key":"1128_CR50","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1096\/fj.11-201608","volume":"26","author":"L Tradtrantip","year":"2012","unstructured":"Tradtrantip L, Zhang H, Anderson MO, Saadoun S, Phuan PW, Papadopoulos MC, Bennett JL, Verkman AS (2012) Small molecule inhibitors of NMO-IgG binding to aquaporin-4 reduce astrocyte cytotoxicity in neuromyelitis optica. FASEB J 26:2197\u20132208","journal-title":"FASEB J"},{"issue":"3","key":"1128_CR51","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/ana.22657","volume":"71","author":"L Tradtrantip","year":"2012","unstructured":"Tradtrantip L, Zhang H, Saadoun S, Phuan PW, Lam C, Papadopoulos MC, Bennett JL, Verkman AS (2012) Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol 71(3):314\u2013322","journal-title":"Ann Neurol"},{"key":"1128_CR52","first-page":"265","volume":"632","author":"E T\u00fcz\u00fcn","year":"2008","unstructured":"T\u00fcz\u00fcn E, Li J, Saini SS, Yang H, Christadoss P (2008) Targeting classical complement pathway to treat complement mediated autoimmune diseases. Adv Exp Med Biol 632:265\u2013272","journal-title":"Adv Exp Med Biol"},{"key":"1128_CR53","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1146\/annurev-pharmtox-010611-134628","volume":"52","author":"K Herle Van","year":"2012","unstructured":"Van Herle K, Behne JM, Van Herle A, Blaschke TF, Smith TJ, Yeaman MR (2012) Integrative continuum: accelerating therapeutic advances in rare autoimmune diseases. Annu Rev Pharmacol Toxicol 52:523\u2013547","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"1","key":"1128_CR54","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00403-008-0895-5","volume":"301","author":"CD Vedove","year":"2009","unstructured":"Vedove CD, Del Giglio M, Schena D, Girolomoni G (2009) Drug-induced lupus erythematosus. Arch Dermatol Res 301(1):99\u2013105","journal-title":"Arch Dermatol Res"},{"key":"1128_CR55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.imbio.2009.08.006","volume":"215","author":"R Wallis","year":"2010","unstructured":"Wallis R, Mitchell DA, Schmid R, Schwaeble WJ, Keeble AH (2010) Paths reunited: initiation of the classical and lectin pathways of complement activation. Immunobiol 215:1\u201311","journal-title":"Immunobiol"},{"key":"1128_CR56","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/ki.2010.472","volume":"79","author":"B Wilde","year":"2011","unstructured":"Wilde B, van Paassen P, Witzke O, Tervaert JW (2011) New pathophysiological insights and treatment of ANCA-associated vasculitis. Kidney Int 79:599\u2013612","journal-title":"Kidney Int"},{"issue":"Suppl 1","key":"1128_CR57","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1007\/s10875-012-9796-7","volume":"33","author":"DM Wingerchuk","year":"2013","unstructured":"Wingerchuk DM (2013) Neuromyelitis optica: potential roles for intravenous immunoglobulin. J Clin Immunol 33(Suppl 1):S33\u2013S37","journal-title":"J Clin Immunol"},{"issue":"9","key":"1128_CR58","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","volume":"6","author":"DM Wingerchuk","year":"2007","unstructured":"Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG (2007) The spectrum of neuromyelitis optica. Lancet Neurol 6(9):805\u2013815","journal-title":"Lancet Neurol"},{"issue":"10","key":"1128_CR59","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","volume":"66","author":"DM Wingerchuk","year":"2006","unstructured":"Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66(10):1485\u20131489","journal-title":"Neurology"},{"key":"1128_CR60","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/978-0-387-71767-8_7","volume":"598","author":"PF Zipfel","year":"2007","unstructured":"Zipfel PF, Mihlan M, Skerka C (2007) The alternative pathway of complement: a pattern recognition system. Adv Exp Med Biol 598:80\u201392","journal-title":"Adv Exp Med Biol"},{"key":"1128_CR61","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nri2620","volume":"9","author":"PF Zipfel","year":"2009","unstructured":"Zipfel PF, Skerka C (2009) Complement regulators and inhibitory proteins. Nature Rev Immunol 9:729\u2013740","journal-title":"Nature Rev Immunol"},{"issue":"6","key":"1128_CR62","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/ana.22551","volume":"70","author":"H Zhang","year":"2011","unstructured":"Zhang H, Bennett JL, Verkman AS (2011) Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms. Ann Neurol 70(6):943\u2013954","journal-title":"Ann Neurol"},{"issue":"5","key":"1128_CR63","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1172\/JCI67554","volume":"123","author":"H Zhang","year":"2013","unstructured":"Zhang H, Verkman AS (2013) Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica. J Clin Invest 123(5):2306\u20132316","journal-title":"J Clin Invest"}],"container-title":["Acta Neuropathologica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-013-1128-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00401-013-1128-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-013-1128-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,26]],"date-time":"2020-07-26T15:40:26Z","timestamp":1595778026000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00401-013-1128-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,16]]},"references-count":63,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["1128"],"URL":"https:\/\/doi.org\/10.1007\/s00401-013-1128-3","relation":{},"ISSN":["0001-6322","1432-0533"],"issn-type":[{"value":"0001-6322","type":"print"},{"value":"1432-0533","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,16]]}}}